Search

The imaging of Prostate-Specific Membrane Antigen (PSMA) is now widely used at the initial staging of prostate cancers in patients with a high metastatic risk. However, its ability to detect low-grade tumor lesions is not optimal., Methods: First, we prospectively performed neurotensin receptor-1 (NTS 1 ) IHC in a series of patients receiving both [ 68 Ga]Ga-PSMA-617 and [ 68 Ga]Ga-RM2 before prostatectomy. In this series, PSMA and GRP-R IHC were also available (n = 16). Next, we aimed at confirming the PSMA/GRP-R/NTS 1 expression profile by retrospective autoradiography (n = 46) using a specific radiopharmaceuticals study and also aimed to decipher the expression of less-investigated targets such as NTS 2 , SST 2 and CXCR4., Results: In the IHC study, all samples with negative PSMA staining (two patients with ISUP 2 and one with ISUP 3) were strongly positive for NTS 1 staining. No samples were negative for all three stains-for PSMA, GRP-R or NTS 1 . In the autoradiography study, binding of [ 111 In]In-PSMA-617 was high in all ISUP groups. However, some samples did not bind or bound weakly to [ 111 In]In-PSMA-617 (9%). In these cases, binding of [ 111 n]In-JMV 6659 and [ 111 In]In-JMV 7488 towards NTS 1 and NTS 2 was high., Conclusions: Targeting PSMA and NTS 1 /NTS 2 could allow for the detection of all intraprostatic lesions.